DrugPatentWatch Database Preview

Drugs in Development Information for QAW039

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug QAW039?

QAW039 is an investigational drug.

There have been 18 clinical trials for QAW039. The most recent clinical trial was a Phase 2 trial, which was initiated on December 7^th 2018.

The most common disease conditions in clinical trials are Asthma, Eosinophilia, and Lung Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are twenty-seven US patents protecting this investigational drug and two hundred and twenty-four international patents.

Summary for QAW039

US Patents	27
International Patents	224
US Patent Applications	76
WIPO Patent Applications	45
Japanese Patent Applications	7
Clinical Trial Progress	Phase 2 (2018-12-07)
Vendors	31

Recent Clinical Trials for QAW039

Title	Sponsor	Phase
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.	Novartis Pharmaceuticals	Phase 2
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia	Novartis Pharmaceuticals	Phase 2
Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma	Novartis Pharmaceuticals	Phase 2

See all QAW039 clinical trials

Clinical Trial Summary for QAW039

Top disease conditions for QAW039

Top clinical trial sponsors for QAW039

See all QAW039 clinical trials

US Patents for QAW039

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
QAW039		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
QAW039		JAK inhibitors containing a 4-membered heterocyclic amide	THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
QAW039		Fused imidazo-piperidine JAK inhibitors	THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
QAW039		Oral drug dosage forms having desired drug release profiles and uses thereof	Triastek, Inc. (Nanjing, CN)
QAW039		Therapeutic compounds and compositions, and methods of use thereof	Genentech, Inc. (South San Francisco, CA)

International Patents for QAW039

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
QAW039	Australia	AU2017261372	2036-05-05
QAW039	Canada	CA3023278	2036-05-05
QAW039	China	CN107847398	2036-05-05
QAW039	European Patent Office	EP3452003	2036-05-05
QAW039	Hong Kong	HK1249728	2036-05-05